Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population.
Gonzalez-Cantero A, Carretero G, Rivera R, Ferrándiz C, Daudén E, de la Cueva P, Gómez-García FJ, Belinchón I, Herrera-Ceballos E, Ruiz-Genao D, Ferrán M, Alsina M, Sánchez-Carazo JL, Baniandrés O, Sahuquillo-Torralba A, Rodriguez L, Vilar J, García C, Carrascosa JM, Llamas-Velasco M, Herrera-Acosta E, López-Estebaranz JL, Botella-Estrada R, Descalzo MA, García-Doval I; BIOBADADERM Study Group. Gonzalez-Cantero A, et al. Br J Dermatol. 2019 Nov;181(5):1085-1087. doi: 10.1111/bjd.18164. Epub 2019 Aug 13. Br J Dermatol. 2019. PMID: 31127858 No abstract available.
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study.
Sahuquillo-Torralba A, Carretero G, Rivera R, Ferrándiz C, Daudén-Tello E, de la Cueva P, Gómez-García FJ, Belinchón I, Herrera-Acosta E, Ruiz-Genao D, Ferrán M, Alsina M, Sánchez-Carazo JL, Baniandrés O, Fernández-Freire LR, Vilar J, García-Donoso C, Carrascosa JM, Llamas-Velasco M, Herrera-Ceballos E, López-Estebaranz JL, Pujol-Marco C, Descalzo MÁ, García-Doval I; Biobadaderm Study Group. Sahuquillo-Torralba A, et al. J Am Acad Dermatol. 2020 Mar;82(3):738-741. doi: 10.1016/j.jaad.2019.07.028. Epub 2019 Jul 13. J Am Acad Dermatol. 2020. PMID: 31306726 Free article. No abstract available.
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, De la Cueva-Dobao P, Gómez-García FJ, Herrera-Ceballos E, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Ortiz PL, García-Doval I, Descalzo MA; Biobadaderm Study Group. Belinchón I, et al. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1700-1708. doi: 10.1111/jdv.14314. Epub 2017 Jun 6. J Eur Acad Dermatol Venereol. 2017. PMID: 28485816
Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort.
Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL, Belinchón-Romero I, Carrascosa JM, Ferrán M, Vanaclocha F, Herrera-Ceballos E, García-Doval I; Biobadaderm Study Group. Ruiz-Genao D, et al. Br J Dermatol. 2017 Mar;176(3):797-799. doi: 10.1111/bjd.14690. Epub 2016 Oct 17. Br J Dermatol. 2017. PMID: 27120993 No abstract available.
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.
García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, de la Cueva P, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group. García-Doval I, et al. J Dermatolog Treat. 2016;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25. J Dermatolog Treat. 2016. PMID: 26367799 Free article.
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, Gómez-García FJ, De la Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Torrado R, Ferrandiz C, Rivera R, Llamas M, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Dávila-Seijo P, et al. J Invest Dermatol. 2017 Feb;137(2):313-321. doi: 10.1016/j.jid.2016.08.034. Epub 2016 Sep 25. J Invest Dermatol. 2017. PMID: 27677836 Free article.
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study.
Descalzo MA, Carretero G, Ferrándiz C, Rivera R, Daudén E, Gómez-García FJ, de la Cueva P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Baniandrés O, Carrascosa JM, Llamas-Velasco M, Ruiz-Genao D, Herrera-Acosta E, Muñoz-Santos C, García-Doval I; Biobadaderm Study Group. Descalzo MA, et al. J Am Acad Dermatol. 2018 Apr;78(4):798-800. doi: 10.1016/j.jaad.2017.10.051. Epub 2017 Nov 13. J Am Acad Dermatol. 2018. PMID: 29146129 Free article. No abstract available.
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
Daudén E, Carretero G, Rivera R, Ferrándiz C, Llamas-Velasco M, de la Cueva P, Belinchón I, Gómez-García FJ, Herrera-Acosta E, Ruiz-Genao DP, Ferrán-Farrés M, Alsina M, Baniandrés-Rodríguez O, Sánchez-Carazo JL, Sahuquillo-Torralba A, Fernández-Freire LR, Vilar-Alejo J, García-Donoso C, Carrascosa JM, Herrera-Ceballos E, López-Estebaranz JL, Botella-Estrada R, Segovia-Muñoz E, Descalzo MA, García-Doval I; BIOBADADERM Study Group. Daudén E, et al. J Am Acad Dermatol. 2020 Jul;83(1):139-150. doi: 10.1016/j.jaad.2020.03.033. Epub 2020 Mar 22. J Am Acad Dermatol. 2020. PMID: 32213306 Free article.
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.
Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Nieto-Benito LM, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferrán Farrés M, Alsina M, Fernández-Freire LR, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Botella-Estrada R, Ruiz-Genao DP, Riera-Monroig J, Descalzo Gallego MÁ, García-Doval I; BIOBADADERM Study Group. Baniandrés-Rodríguez O, et al. J Am Acad Dermatol. 2021 Feb;84(2):513-517. doi: 10.1016/j.jaad.2020.10.046. Epub 2020 Oct 26. J Am Acad Dermatol. 2021. PMID: 33122022 Free PMC article. No abstract available.
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.
Munera-Campos M, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Baniandrés-Rodríguez O, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferran M, Riera-Monroig J, Rodriguez L, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Pujol-Marco C, Nieto-Benito LM, Ruiz-Genao DP, Alsina M, Descalzo MA, García-Doval I; BIOBADADERM Study Group. Munera-Campos M, et al. Among authors: herrera ceballos e. J Dermatolog Treat. 2022 Jun;33(4):2110-2117. doi: 10.1080/09546634.2021.1922572. Epub 2022 Mar 23. J Dermatolog Treat. 2022. PMID: 33913796 Free article.
88 results